US stock · Healthcare sector · Drug Manufacturers—General
Company Logo

Gilead Sciences, Inc.

GILDNASDAQ

64.47

USD
-0.54
(-0.83%)
Market Closed
18.01P/E
10Forward P/E
0.69P/E to S&P500
80.865BMarket CAP
4.40%Div Yield

Gilead Sciences, Inc.

NASDAQ:GILD

RECENT
PRICE

64.47

P/E
RATIO

18.01

(PEG:0.00)

P/E RATIO
RELATIVE
TO S&P

0.69

DIV
YLD

4.34%

High:
Low:

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

Legends

Stock price

- - Beta (1.0 Market)

0

0

0

0

0

0

0

0

0

-

% total return 05/22:

Stock

S&P

1y.

0

0

3y.

0

0

5y.

0

0

0

Percent shares traded:

0

0

0

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

TTM

Fiscal year

1.65

(0.65)

0.61

- -

2.28

0.87

0.91

- -

2.90

1.09

1.13

- -

3.88

1.46

1.58

- -

4.64

1.69

1.62

- -

5.41

1.81

2.26

- -

6.41

1.71

1.85

- -

7.33

2.01

1.91

- -

16.35

7.95

8.06

- -

22.29

12.37

13.38

1.28

22.70

10.08

11.89

1.83

19.97

3.54

8.65

2.09

17.05

4.20

5.76

2.29

17.68

4.24

6.55

2.54

19.64

0.10

5.98

2.74

21.74

4.96

8.60

2.87

21.88

3.59

7.93

2.89

Revenue per share

Earnings per share

Free Cash Flow per sh

Dividends per share

0.06

0.99

0.04

1.86

0.06

2.26

0.13

3.52

0.04

3.42

0.09

4.35

0.26

6.15

0.12

7.44

0.37

10.14

0.51

12.66

0.56

14.11

0.45

15.64

0.71

16.48

0.65

17.74

0.52

14.48

0.46

16.77

0.53

16.36

CAPEX per share

Book Value per share

1,836

1,858

1,841

1,809

1,712

1,550

1,515

1,529

1,522

1,464

1,339

1,307

1,298

1,270

1,257

1,256

1,256

Comm.Shares outs.(m)

(23.8)

(1.3)

- -

22.8

1.3

- -

22.4

1.0

- -

15.8

0.2

- -

11.6

0.6

- -

11.0

0.7

- -

16.5

1.1

- -

27.7

1.6

- -

11.2

0.6

- -

8.5

0.4

1.2%

8.3

0.4

2.2%

20.5

0.9

2.9%

17.5

0.7

3.1%

15.4

0.6

3.9%

706.3

18.7

4.0%

13.6

0.5

4.3%

18.0

0.7

4.3%

Avg. annual P/E ratio

P/E relative to S&P500

Avg. annual div. yield

Capital Structure (31/3/22 | Q1)

Total liabilities
$43,165 m.

Total assets
$63,080 m.

Long-term debt
$25,183 m.

Cash and equiv.
$4,296 m.

Goodwill $8,314 m.

Retained earnings $14,986 m.

Common stock 1,255 m. shares

Market Capitalisation
$80,865 m. (as of 27/5/22)

8,385

45.2%

9,703

41.3%

11,202

40.4%

24,890

61.3%

32,639

68.0%

30,390

58.0%

26,107

54.1%

22,127

37.1%

22,449

19.1%

24,689

16.5%

27,305

36.3%

27,472

26.0%

Revenue (m)

Operating margin

302

2,804

278

2,592

345

3,075

1,050

12,101

1,098

18,108

1,158

13,501

1,286

4,628

1,429

5,455

1,404

5,386

1,480

123

2,050

6,225

2,102

4,515

Depreciation (m)

Net profit (m)

23.6%

33.4%

28.7%

26.7%

27.3%

27.4%

18.8%

48.6%

16.4%

55.5%

21.1%

44.4%

65.7%

17.7%

30.0%

24.7%

(4.0)%

24.0%

94.7%

0.5%

25.1%

22.8%

49.9%

16.2%

Income tax rate

Net profit margin

11,404

7,606

6,739

1,886

7,055

9,310

948

3,939

11,369

11,953

11,921

15,426

14,872

21,195

18,534

11,226

26,346

18,887

20,188

30,795

20,442

25,231

24,574

21,387

20,537

22,094

22,525

4,599

28,645

18,202

3,162

25,179

21,069

4,071

25,183

19,927

Working capital (m)

Long-term debt (m)

Equity (m)

20.2%

22.5%

41.6%

17.0%

19.0%

27.8%

20.8%

20.5%

27.0%

43.6%

44.7%

78.4%

45.2%

43.6%

97.7%

30.2%

32.0%

71.5%

8.6%

20.8%

22.6%

11.7%

14.0%

25.5%

12.4%

10.0%

23.9%

0.3%

3.9%

0.7%

12.4%

13.7%

29.5%

6.3%

10.9%

22.7%

ROIC

Return on capital

Return on equity

Working Capital

2019

2020

2021

Cash assets

24,352

18,718

18,059

Receivables

3,582

4,892

4,493

Inventory

922

1,683

1,618

Other

1,440

2,013

2,141

Current assets

30,296

15,996

14,772

Acc. Payable

713

844

705

Debt due

2,499

2,757

1,516

Other

6,547

7,796

9,389

Current liab.

9,759

11,397

11,610

100.0%

61.9%

100.0%

7.2%

100.0%

9.2%

100.0%

40.9%

89.7%

59.0%

81.8%

83.2%

41.0%

30.5%

45.5%

74.7%

40.2%

57.2%

(2,704.1)%

63.5%

42.1%

36.9%

19.4%

40.7%

Plowback ratio

Div.&Repurch. to FCF

Gilead Sciences, Inc. (US) started trading on January 3, 1992 (cik: 0000882095), operates in the Healthcare sector (Drug Manufacturers—General industry), has 14,400 full-time employees, and is led by Mr. Daniel O'Day. Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Annual rates

(avg rate of change)

Past
5 y.

Past
10 y.

Revenues

1.70%

17.18%

Cash flow

2.87%

38.71%

Earnings

1219.97%

572.28%

Dividends

7.20%

- -

Book value

1.63%

10.51%

Insider trading

Type

Shares

Date

Barton Jacqueline K

Award

15,851

05/05/22

Barton Jacqueline K

Award

2,444

05/05/22

Lofton Kevin E

Award

15,851

05/05/22

Lofton Kevin E

Award

2,444

05/05/22

Bluestone Jeffrey

Award

15,851

05/05/22

Fiscal Year Ends

Quarterly Revenue (m)

Full fiscal year

I

II

III

IV

2020

5,548

5,143

6,577

7,421

24,689

2021

6,423

6,217

7,421

7,244

27,305

2022

6,590

- -

- -

- -

- -

Fiscal Year Ends

Earnings per share

Full fiscal year

I

II

III

IV

2020

1.23

(2.66)

0.29

1.23

0.10

2021

1.38

1.21

2.06

0.30

4.96

2022

0.02

- -

- -

- -

- -

Fiscal Year Ends

Quarterly dividends paid

Full fiscal year

I

II

III

IV

2020

0.70

0.68

0.68

0.68

2.74

2021

0.73

0.71

0.72

0.71

2.87

2022

0.75

- -

- -

- -

- -

03/30/2022

Justice Department Probes Alleged Sales of Counterfeit HIV Drugs

The Wall Street Journal - Read more...

02/01/2022

Gilead’s Revenue Declines on Waning Sales of Covid-19 Drug

The Wall Street Journal - Read more...

01/18/2022

Gilead Alleges Counterfeiting Ring Sold Its HIV Drugs

The Wall Street Journal - Read more...

12/22/2021

Gilead’s Remdesivir Covid-19 Therapy Cuts Risk of Hospitalization in Study

The Wall Street Journal - Read more...

07/30/2021

Amazon, Pinterest, Robinhood, Chevron: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

07/29/2021

Robinhood, Didi Global, Facebook, Credit Suisse: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

06/23/2021

Illicit Covid-19 Drugs Bound for Mexico Seized by U.S. Authorities

The Wall Street Journal - Read more...

04/30/2021

Twitter, Amazon, Clorox, Chevron: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

04/29/2021

Facebook, Twitter, eBay, Apple: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

03/15/2021

Gilead and Merck Join Forces to Develop Long-Acting HIV Treatment

The Wall Street Journal - Read more...

02/05/2021

Pinterest, Activision Blizzard, Peloton: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

02/04/2021

PayPal, eBay, Qualcomm: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

01/11/2021

Eli Lilly, Twitter, NIO: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

12/10/2020

Gilead to Pay $1.4 Billion for Hepatitis Drugmaker MYR GmbH

The Wall Street Journal - Read more...

11/20/2020

Pfizer, Gilead, Ross: What to Watch When the Stock Market Opens Today

The Wall Street Journal - Read more...

11/20/2020

WHO Recommends Against Use of Gilead Covid-19 Drug Remdesivir

The Wall Street Journal - Read more...

10/28/2020

Gilead Quarterly Revenue Rises on Remdesivir Sales

The Wall Street Journal - Read more...

10/01/2020

All Remdesivir Supplies to Be Distributed in U.S. by Maker Gilead

The Wall Street Journal - Read more...

09/14/2020

Gilead Reaches Deal to Buy Immunomedics for $21 Billion

The Wall Street Journal - Read more...

09/13/2020

Gilead’s $20 Billion Gamble

The Wall Street Journal - Read more...

08/07/2020

Gilead Inks Deal to Boost Production of Covid-19 Drug Remdesivir

The Wall Street Journal - Read more...

07/30/2020

Gilead Raises 2020 Profit Outlook on Remdesivir Demand

The Wall Street Journal - Read more...

07/16/2020

Russian Hackers Blamed for Attacks on Vaccine-Related Targets

The Wall Street Journal - Read more...